DK164870C - Fremgangsmaade til fremstilling af acarbose med et acarbose-indhold paa mindst 90 vaegtprocent paa toerstofbasis, eller en vandig oploesning deraf - Google Patents

Fremgangsmaade til fremstilling af acarbose med et acarbose-indhold paa mindst 90 vaegtprocent paa toerstofbasis, eller en vandig oploesning deraf

Info

Publication number
DK164870C
DK164870C DK598686A DK598686A DK164870C DK 164870 C DK164870 C DK 164870C DK 598686 A DK598686 A DK 598686A DK 598686 A DK598686 A DK 598686A DK 164870 C DK164870 C DK 164870C
Authority
DK
Denmark
Prior art keywords
acarbose
weight
procedure
preparation
aqueous solution
Prior art date
Application number
DK598686A
Other languages
English (en)
Other versions
DK598686D0 (da
DK598686A (da
DK164870B (da
Inventor
Erich Rauenbusch
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6288309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK164870(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of DK598686D0 publication Critical patent/DK598686D0/da
Publication of DK598686A publication Critical patent/DK598686A/da
Publication of DK164870B publication Critical patent/DK164870B/da
Application granted granted Critical
Publication of DK164870C publication Critical patent/DK164870C/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/08—Deoxysugars; Unsaturated sugars; Osones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/22—Cyclohexane rings, substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Treatment Of Sludge (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Electrotherapy Devices (AREA)
DK598686A 1985-12-13 1986-12-12 Fremgangsmaade til fremstilling af acarbose med et acarbose-indhold paa mindst 90 vaegtprocent paa toerstofbasis, eller en vandig oploesning deraf DK164870C (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19853543999 DE3543999A1 (de) 1985-12-13 1985-12-13 Hochreine acarbose
DE3543999 1985-12-13

Publications (4)

Publication Number Publication Date
DK598686D0 DK598686D0 (da) 1986-12-12
DK598686A DK598686A (da) 1987-06-14
DK164870B DK164870B (da) 1992-08-31
DK164870C true DK164870C (da) 1993-01-11

Family

ID=6288309

Family Applications (1)

Application Number Title Priority Date Filing Date
DK598686A DK164870C (da) 1985-12-13 1986-12-12 Fremgangsmaade til fremstilling af acarbose med et acarbose-indhold paa mindst 90 vaegtprocent paa toerstofbasis, eller en vandig oploesning deraf

Country Status (12)

Country Link
US (1) US4904769A (da)
EP (1) EP0226121B1 (da)
JP (2) JP2502551B2 (da)
KR (1) KR940004065B1 (da)
CN (1) CN1013866B (da)
AT (1) ATE71951T1 (da)
BG (1) BG49497A3 (da)
CA (1) CA1288768C (da)
DE (2) DE3543999A1 (da)
DK (1) DK164870C (da)
ES (1) ES2038591T3 (da)
HU (1) HU196219B (da)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
IT1293819B1 (it) * 1997-08-05 1999-03-10 Univ Massachusetts Lowell Procedimento per la preparazione di acarbosio
DE19802700A1 (de) * 1998-01-24 1999-07-29 Bayer Ag Verfahren zur Herstellung einer im Mund schnell zerfallenden Arzneiform, die als Wirkstoff Acarbose enthält
AP1224A (en) 1998-03-19 2003-11-14 Bristol Myers Squibb Co Biphasic controlled release delivery system for high solubility pharmaceuticals and method.
CZ2001965A3 (cs) 1998-09-17 2002-02-13 Bristol-Myers Squibb Company Lék pro oąetřování atherosklerózy nebo diabetes typu II, farmaceutická kombinace a její pouľití
KR100383435B1 (ko) * 1999-10-28 2003-05-12 주식회사종근당 고순도 아카보스 제조방법
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
EP1741445B1 (en) 2000-01-21 2013-08-14 Novartis AG Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
ATE343391T1 (de) * 2000-05-24 2006-11-15 Pfizer Behandlung von pansenacidose mit amylasehemmern
JP2004505913A (ja) 2000-08-07 2004-02-26 ランバクシー　シグネチャー，エルエルシー メトフォルミンの液体処方
AU2001284741A1 (en) * 2000-08-07 2002-02-18 Biogal Gyogyszergyar Rt Method for purification of acarbose
FI20002148L (fi) * 2000-09-29 2002-03-30 Xyrofin Oy Menetelmä tuotteiden talteenottamiseksi
FI20002149L (fi) * 2000-09-29 2002-03-30 Xyrofin Oy Sakkaridien puhdistaminen kromatografisella erotuksella
FR2816840B1 (fr) * 2000-11-17 2004-04-09 Flamel Tech Sa Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
US6849609B2 (en) 2001-04-10 2005-02-01 James U. Morrison Method and composition for controlled release acarbose formulations
ATE318272T1 (de) 2001-04-11 2006-03-15 Bristol Myers Squibb Co Aminosäurekomplexe von c-arylglycosiden zur behandlung von diabetes und verfahren
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
HRP20010792A2 (en) 2001-10-26 2003-04-30 Pliva D D Acarbose purification process
US6806381B2 (en) * 2001-11-02 2004-10-19 Bristol-Myers Squibb Company Process for the preparation of aniline-derived thyroid receptor ligands
US6984645B2 (en) * 2001-11-16 2006-01-10 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
FR2834214B1 (fr) * 2001-12-28 2004-09-24 Lipha Composition pharmaceutique comprenant un inhibiteur d'alpha-glucosidase et un acide 4-oxo-butanoique et son utilisation pour traiter le diabete
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
JP4698950B2 (ja) * 2002-04-09 2011-06-08 フラメル・テクノロジー アモキシシリンの改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤
CN100553625C (zh) 2002-04-09 2009-10-28 弗拉梅技术公司 活性成分微囊的口服混悬液
US20040018990A1 (en) * 2002-07-25 2004-01-29 Harvey Rosner Treatment of obesity
TW200504021A (en) * 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
WO2004066929A2 (en) * 2003-01-24 2004-08-12 Bristol-Myers Squibb Company Cycloalkyl containing anilide ligands for the thyroid receptor
US7459474B2 (en) * 2003-06-11 2008-12-02 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US7371759B2 (en) * 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7674913B2 (en) 2003-11-12 2010-03-09 Phenomix Corporation Heterocyclic boronic acid compounds
US7420059B2 (en) * 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
CN1296050C (zh) * 2003-12-10 2007-01-24 浙江海正药业股份有限公司 阿卡波糖肠溶片及制备方法
WO2006017292A1 (en) * 2004-07-12 2006-02-16 Phenomix Corporation Constrained cyano compounds
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
DE102004042139B4 (de) * 2004-08-31 2009-06-10 Aristocon Verwaltungs- Gmbh Perorale Darreichungsformen zur Erzielung eines Retardierungseffektes nach der Arzneimitteleinnahme mit einer Mahlzeit
CN101432004A (zh) * 2004-09-14 2009-05-13 伊利舍医药品公司 用于控制的碳水化合物消化的联合治疗
US7517991B2 (en) * 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
WO2006076597A1 (en) * 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US7361766B2 (en) 2005-01-12 2008-04-22 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US7314882B2 (en) * 2005-01-12 2008-01-01 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US7317024B2 (en) 2005-01-13 2008-01-08 Bristol-Myers Squibb Co. Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
WO2006078697A1 (en) * 2005-01-18 2006-07-27 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
WO2006086464A2 (en) * 2005-02-10 2006-08-17 Bristol-Myers Squibb Company Dihydroquinazolinones as 5ht modulators
US7888381B2 (en) 2005-06-14 2011-02-15 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof
US7629342B2 (en) * 2005-06-17 2009-12-08 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
US7452892B2 (en) * 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
TW200726765A (en) * 2005-06-17 2007-07-16 Bristol Myers Squibb Co Triazolopyridine cannabinoid receptor 1 antagonists
US20060287342A1 (en) * 2005-06-17 2006-12-21 Mikkilineni Amarendra B Triazolopyrimidine heterocycles as cannabinoid receptor modulators
US7632837B2 (en) * 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
US7317012B2 (en) * 2005-06-17 2008-01-08 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoind-1 receptor modulators
AU2006275694A1 (en) * 2005-07-28 2007-02-08 Bristol-Myers Squibb Company Substituted tetrahydro-1H-pyrido(4,3,b)indoles as serotonin receptor agonists and antagonists
US7795436B2 (en) * 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
CN101325959A (zh) * 2005-09-14 2008-12-17 伊利舍医药品公司 用于受控碳水化合物消化的联合疗法
CA2622608C (en) 2005-09-14 2014-08-19 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetes
US8618115B2 (en) 2005-10-26 2013-12-31 Bristol-Myers Squibb Company Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7553836B2 (en) * 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
US20070238770A1 (en) * 2006-04-05 2007-10-11 Bristol-Myers Squibb Company Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
KR20090040906A (ko) * 2006-08-02 2009-04-27 유나이티드 세러퓨틱스 코오포레이션 바이러스 감염의 리포솜 치료
CA2666814A1 (en) * 2006-08-21 2008-05-29 United Therapeutics Corporation Combination therapy for treatment of viral infections
US7968577B2 (en) 2006-11-01 2011-06-28 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
JP2010508358A (ja) 2006-11-01 2010-03-18 ブリストル−マイヤーズ スクイブ カンパニー グルココルチコイド受容体、ＡＰ−１、および／またはＮＦ−κＢ活性の調節剤、並びにその使用
CN100572549C (zh) * 2007-02-01 2009-12-23 华东医药股份有限公司 高纯度阿卡波糖的制备方法
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US20090011994A1 (en) * 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
EP2209780B1 (en) 2007-11-01 2014-01-01 Bristol-Myers Squibb Company Nonsteroidal compounds useful as modulators of glucocorticoid receptor ap-1 and/or nf- kappa b activity and use thereof
WO2009118658A2 (en) * 2008-03-26 2009-10-01 University Of Oxford Endoplasmic reticulum targeting liposomes
PE20091928A1 (es) * 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
CA2756786A1 (en) 2009-03-27 2010-09-30 Bristol-Myers Squibb Company Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors
EP2410989A2 (en) * 2009-03-27 2012-02-01 The Chancellor, Masters and Scholars of the University of Oxford Cholesterol level lowering liposomes
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
SI2531501T1 (sl) 2010-02-03 2014-04-30 Takeda Pharmaceutical Company Limited Inhibitorji kinaze-1, ki regulirajo signal apoptoze
CN103153288B (zh) 2010-07-09 2017-02-15 詹姆斯·特林卡·格林 用于包括瑞格列净的短半衰期药物的组合立即/延迟释放递送系统
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN102030786A (zh) * 2010-11-12 2011-04-27 丽珠集团新北江制药股份有限公司 一种阿卡波糖的制备方法
WO2014039411A1 (en) 2012-09-05 2014-03-13 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormore receptor-1 antagonists
EP2892897A1 (en) 2012-09-05 2015-07-15 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
WO2014057522A1 (en) 2012-10-12 2014-04-17 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US10441560B2 (en) 2013-03-15 2019-10-15 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
WO2014142364A2 (en) 2013-03-15 2014-09-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
CN105764916B (zh) 2013-06-05 2021-05-18 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
US9593113B2 (en) 2013-08-22 2017-03-14 Bristol-Myers Squibb Company Imide and acylurea derivatives as modulators of the glucocorticoid receptor
CN104597171A (zh) * 2013-10-31 2015-05-06 江苏万邦生化医药股份有限公司 阿卡波糖及其制剂的高效液相色谱分析方法
CN113670680B (zh) * 2021-06-30 2024-08-27 杭州中美华东制药江东有限公司 阿卡波糖杂质对照品的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2347782C3 (de) * 1973-09-22 1979-10-11 Bayer Ag, 5090 Leverkusen Aminozuckerderivate, Verfahren zu ihrer Herstellung sowie diese Verbindungen enthaltende Arzneimittel
US4062950A (en) * 1973-09-22 1977-12-13 Bayer Aktiengesellschaft Amino sugar derivatives
DE2719912C3 (de) * 1977-05-04 1979-12-06 Bayer Ag, 5090 Leverkusen Verfahren zur Isolierung von 0- |4,6-Dideoxy-4- [JJl S-O,4,6/5)-4,5,6-trihydroxy-3-hydroxymethyl-2cyclohexen-1-yl] -amino] - a -D-glucopyranosyl} -(I Pfeil nach rechts 4)-0- a D-glucopyranosyl-(l Pfeil nach rechts 4)-D-glucopyranose aus Kulturbrühen
US4526784A (en) * 1981-05-05 1985-07-02 Bayer Aktiengesellschaft Amino-cyclitol derivatives and medicaments containing them
DE3123520A1 (de) * 1981-06-13 1982-12-30 Bayer Ag, 5090 Leverkusen Gesaettigte aminocyclitderivate, ihre herstellung undsie enthaltende arzneimittel
DE3439008A1 (de) * 1984-10-25 1986-04-30 Bayer Ag, 5090 Leverkusen Polymerisate zur reinigung von acarbose

Also Published As

Publication number Publication date
KR940004065B1 (ko) 1994-05-11
JP2628853B2 (ja) 1997-07-09
US4904769A (en) 1990-02-27
DK598686D0 (da) 1986-12-12
JPH08245683A (ja) 1996-09-24
DE3543999A1 (de) 1987-06-19
CN86108259A (zh) 1987-07-29
CA1288768C (en) 1991-09-10
DK598686A (da) 1987-06-14
EP0226121A2 (de) 1987-06-24
ES2038591T3 (es) 1993-08-01
DE3683611D1 (de) 1992-03-05
EP0226121B1 (de) 1992-01-22
JP2502551B2 (ja) 1996-05-29
KR870006074A (ko) 1987-07-09
HUT43083A (en) 1987-09-28
DK164870B (da) 1992-08-31
CN1013866B (zh) 1991-09-11
JPS62155288A (ja) 1987-07-10
EP0226121A3 (en) 1989-03-22
HU196219B (en) 1988-10-28
ATE71951T1 (de) 1992-02-15
BG49497A3 (en) 1991-11-15

Similar Documents

Publication Publication Date Title
DK164870C (da) Fremgangsmaade til fremstilling af acarbose med et acarbose-indhold paa mindst 90 vaegtprocent paa toerstofbasis, eller en vandig oploesning deraf
DE69018172D1 (de) Natriumbicarbonat enthaltende Zusammensetzung zur Herstellung einer Dialyselösung.
DK162814C (da) Tabletter med kontrolleret afgivelse, indeholdende naproxen eller naproxennatrium
DK87782A (da) Fremgangsmaade til fremstilling af imidazodiazepiner eller farmaceutisk acceptable syreadditionssalte deraf samt ved fremgangsmaaden anvendelige mellemprodukter
DK148745C (da) Ribofuranosylderivater til anvendelse som mellemprodukter ved fremstilling af 5'-deoxy-5-fluorcytidin eller 5'-deoxy-5-fluoruridin eller fysiologisk tolerable syreadditionssalte deraf
DK341281A (da) Fremgangsmaade til fremstilling af 3,3-dialkyldenzodiazepinderivater eller syreadditionssalte deraf samt ved fremgangsmaaden som mellemprodukter anvendelige forbindelrser
DK74382A (da) Fremgangsmaade til fremstilling af imidazodiazepiner eller farmaceutisk acceptable syreadditionssalte deraf samt ved fremgangsmaaden anvendelige mellemprodukter
DK90494A (da) Fremgangsmåde til fremstilling af 2,3,4,5,-tetrafluorbenzoesyre
DK69382A (da) Fremgangsmaade til fremstilling af azepinderivater eller saltederaf
DK134580A (da) Fremgangsmaade til fremstilling af 2,6-diaminonebulariner eller syreadditionssalte deraf
IT8048909A0 (it) Procedimento per la preparazione di solfenammidi
DK641187D0 (da) Fremgangsmaade til fremstilling af vandfri alkansulfonsyre
AR223663A1 (es) Procedimiento para la preparacion de derivados 1,6-disustituidos de acido 4-piridon-3-carboxilico
DK382979A (da) Fremgangsmaade til fremstilling af 3" , 4"-diacyltylosinderivater
NO792002L (no) Fremgangsmaate til fremstilling av 2,2'-ditio-bis-(benzamid)-derivater eller salter av noen av derivatene
DK164379A (da) Fremgangsmaade til fremstilling af 7-methoxy-5-oxo-5h-thiazolo(2,3-b)quinazolin-2-carboxylsyre eller farmaceutisk anvendelige salte deraf
DK540283A (da) Fremgangsmaade til fremstilling af thienyleddikesyreamider eller fysiologisk taalelige syreadditionssalte deraf
MX159288A (es) Procedimiento para la preparacion de derivados de 3,7-diazabisiclo(3,3-1)nonano
DK449882A (da) Analogifremgangsmaade til fremstilling af spiro-(indolin-3,5'-oxazolidin)-2,2',4'-trion-derivater eller basesalte deraf med farmakologisk acceptable kationer
ES515227A0 (es) "procedimiento para la preparacion de composiciones poliolefinicas autoextinguentes".
DK150481C (da) Analogifremgangsmaade til fremstilling af 3',4'-dihydro-spiro-(imidazolidin-4,1'-(2'h)-naphthalen)-5-on eller farmaceutisk acceptable syreadditionssalte deraf
DK10486D0 (da) Fremgangsmaade til fremstilling af ranitidin eller hydrokloridet deraf
DK398283D0 (da) Fremgangsmade til fremstilling af 1,4-dihydropyridinderivater eller farmaceutisk acceptable syreadditionssalte deraf
DK258180A (da) Fremgangsmaade til fremstilling af pyridylaminotriazoler eller syreadditionssalte deraf
NO863735D0 (no) Fremgangsmaate for fremstilling av ranitidin eller syreaddisjonssalter derav.

Legal Events

Date Code Title Description
A0 Application filed
PUP Patent expired